These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23819792)

  • 1. Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
    Vazakidou ME; Magkouta S; Moschos C; Kalomenidis I
    Respirology; 2014 Feb; 19(2):290-292. PubMed ID: 23819792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.
    Psallidas I; Stathopoulos GT; Maniatis NA; Magkouta S; Moschos C; Karabela SP; Kollintza A; Simoes DC; Kardara M; Vassiliou S; Papiris SA; Roussos C; Kalomenidis I
    Oncogene; 2013 Jan; 32(4):528-35. PubMed ID: 22370646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha promotes malignant pleural effusion.
    Stathopoulos GT; Kollintza A; Moschos C; Psallidas I; Sherrill TP; Pitsinos EN; Vassiliou S; Karatza M; Papiris SA; Graf D; Orphanidou D; Light RW; Roussos C; Blackwell TS; Kalomenidis I
    Cancer Res; 2007 Oct; 67(20):9825-34. PubMed ID: 17942913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo.
    Vazakidou ME; Magkouta S; Moschos C; Psallidas I; Pappas A; Psarra K; Kalomenidis I
    Respirology; 2015 Nov; 20(8):1263-71. PubMed ID: 26245309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion.
    Magkouta S; Pappas A; Moschos C; Vazakidou ME; Psarra K; Kalomenidis I
    Oncotarget; 2016 Apr; 7(15):20249-59. PubMed ID: 26959120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast cells mediate malignant pleural effusion formation.
    Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
    J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
    Marazioti A; Kairi CA; Spella M; Giannou AD; Magkouta S; Giopanou I; Papaleonidopoulos V; Kalomenidis I; Snyder LA; Kardamakis D; Stathopoulos GT
    PLoS One; 2013; 8(8):e71207. PubMed ID: 23967166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
    Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
    Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
    Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
    Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells.
    Acencio MM; Puka J; Marchi E; Antonangelo L; Terra RM; Vargas FS; Capelozzi VL; Teixeira LR
    J Transl Med; 2015 Sep; 13():302. PubMed ID: 26373420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
    Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
    Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
    Yeh HH; Lai WW; Chen HH; Liu HS; Su WC
    Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutical effects of pleural injecting recombinant human endostain to 
malignant pleural effusion nude mice model].
    Zhou M; Li M; Yang H; Hu C
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):266-71. PubMed ID: 25975296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
    Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
    J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
    Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
    Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
    Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
    Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
    Ohara T; Takaoka M; Toyooka S; Tomono Y; Nishikawa T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
    Cancer Sci; 2011 Jul; 102(7):1344-9. PubMed ID: 21521416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant KRAS promotes malignant pleural effusion formation.
    Agalioti T; Giannou AD; Krontira AC; Kanellakis NI; Kati D; Vreka M; Pepe M; Spella M; Lilis I; Zazara DE; Nikolouli E; Spiropoulou N; Papadakis A; Papadia K; Voulgaridis A; Harokopos V; Stamou P; Meiners S; Eickelberg O; Snyder LA; Antimisiaris SG; Kardamakis D; Psallidas I; Marazioti A; Stathopoulos GT
    Nat Commun; 2017 May; 8():15205. PubMed ID: 28508873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Arsenic Trioxide in the Treatment of Malignant Pleural Effusion Caused by Pleural Metastasis of Lung Cancer.
    Xie SL; Yang MH; Chen K; Huang H; Zhao XW; Zang YS; Li B
    Cell Biochem Biophys; 2015 Apr; 71(3):1325-33. PubMed ID: 25413961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.